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The p53 tumor suppressor protein is one of the major regulators of cell proliferation and death. Therefore, p53 is considered a key 
protein in cancer development. The activity and stability of p53 are regulated by the endogenous negative regulator, MDM2. Hence the 
discovery of inhibitors of p53–MDM2 interaction is considered a promising strategy for cancer treatment.
[1]
 Chalcones represent an 
outstanding class of plant secondary metabolites, which have long been recognized for their pharmacological properties, being the 
antitumor activity one of the most extensively studied. Previous studies from our research group have shown potent growth inhibitory 
effects of several prenylchalcones against distinct human tumor cell lines.
[2]
 Taking this in consideration, and with the objective of 
obtaining chalcones with potential antitumor activity by interfering with the p53–MDM2 interaction, several prenylchalcones were 
synthesized using the chalcone as building block with prenyl bromide in presence of tetrabutylammonium hydroxide at room 
temperature. Structure elucidation was performed by NMR techniques (
1
H NMR, 
13
C NMR, HSQC and HMBC). The effect of the 
synthesized chalcones on the p53–MDM2 interaction was evaluated using a yeast-based assay, consisting of Saccharomyces cerevisae 
cells co-expressing human p53 and MDM2, as described previously.
[3]
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Hydrazone derivatives constitute a class of compounds intensively investigated as target for drug development. Experimental and 
preclinical models demonstrated that a number of these compounds elicited outstanding anticancer activity through a range of 
biological activities implicated with the development and maintenance of tumor cells. Recently, 
we have reported the synthesis and in vitro antitumor activity of various heterocyclic 
acylhydrazone derivatives. Several of tested compounds exhibited in vitro excellent 
antiproliferative effect against the NCI full panel cell lines, showing low micromolar to nanomolar 
GI50 inhibitory values, and no sign of acute toxicity in athymic nudes mice.
[1]
 In a previous study, 
we reported some arylidenehydrazinopyrimidines endowed with inhibitory effects on the growth 
of a wide range of cancer cell lines generally at 10
−5
 M to 10
−7
 M concentrations.
[2]
 Within the 
context of our research program, we designed new 2-(arylidenehydrazino)pyrrole derivatives in 
order to be evaluated as potential antitumor agents (see Figure). The synthesis of a series of 
these compounds, results of the in vitro antiproliferative activity, and initial SAR study are 
discussed. 
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Cancer is the second cause of death in USA and this term represents a group of diseases characterized by an untypical growth of 
cells in different tissues.
[1]
 The treatment is based on use of one or more drugs able to interfere at cell division cycle.
[2]
 Among these 
chemotherapies, those who interrupt the microtubules dynamic, like vincristine and paclitaxel, were demonstrated to have high efficacy 
in treatment of several tumors. Therefore, compounds able to inhibit tubulin polymerization are considered a promise cytotoxic agent 
with potential antitumor activity.
[3,4]
 
Based on combretastatin A4 (CA-4), a natural stilbene isolated from Combretum caffrum, that binds to the colchicine domain on  
b-tubulin and acts as anti-microtubule agent, a congener series of N-acylhydrazone derivatives were designed as CA4 analogues. Herein, 
we describe the docking studies, the synthesis and the antiproliferative activity against different human tumor cell lines (HL-60, SF295, 
MDA-MB435, HCT-8, PC3M, OVCAR-8 and NCI-H358M) of these N-acylhydrazone derivatives. The main structural requirements 
essential to molecular recognition process by the colchicine binding site of b-tubulin were recognized and several compounds with 
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